High Risk Smoldering Multiple Myeloma Clinical Trials

10 clinical trials for High Risk Smoldering Multiple Myeloma across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) — RECRUITING · PHASE3
• A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma — RECRUITING · PHASE2
• BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma — RECRUITING · NA
• Immuno-PRISM (PRecision Intervention Smoldering Myeloma) — RECRUITING · PHASE2
• Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma — RECRUITING · PHASE2
• Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma (GEM-CAR-HiRiSMM) — TERMINATED · PHASE2
• DARA RVD For High Risk SMM — ACTIVE_NOT_RECRUITING · PHASE2
• Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study — COMPLETED · PHASE1
• Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients — TERMINATED · PHASE2
• A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma — COMPLETED · PHASE2

Refine this search